샘플 요청 목록

 카트 문의
시장보고서
상품코드
1514897

비강 백신 시장 : 부문별, 국가 및 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2024-2032년)

Nasal Vaccines Market, By Vaccine Type, By Delivery Method, By Distribution, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
발행일: | 리서치사: AnalystView Market Insights | 페이지 정보: 영문 357 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

비강 백신(Nasal Vaccines) 시장 규모는 2023년 4억 1890만 달러였으며, 2024년부터 2032년까지 CAGR 8.56%로 추이하며 확대 할 것으로 예상됩니다.

비강 백신 시장-시장 역학

호흡기 감염의 유병률 증가가 시장 성장을 가속

호흡기 감염의 유병률 증가는 비강 백신 시장 성장에 박차를 가하고 있습니다. 이 기술은 주사 바늘을 사용하지 않는 예방 접종의 대안을 제공하기 위해서입니다. 세계보건기구(WHO)에 따르면 호흡기 감염은 세계 사망률의 대부분을 차지하고 있으며, 인플루엔자만으로도 연간 29만-65만명이 사망하고 있는 것으로 추정되고 있습니다. 이 부담은 바늘을 사용하지 않는 예방 접종에 대한 선호 증가와 함께 비강 백신 시장을 견인하고 있습니다. 예를 들어, 유명한 의학 잡지에 게재된 최근의 연구는 RSV(호흡기 합포체 바이러스)에 대한 비강 백신이 유아의 보호에 효과적임을 입증하고 그 가능성을 강조하였습니다. 호흡기 질환과의 싸움이 계속되는 가운데, 비강 백신은 더 중요한 역할을 할 것으로 보입니다.

비강 백신 시장-주요 통찰력

리서치 애널리스트 분석에 따르면 세계 시장은 예측 기간(2024-2032년)에 약 8.56%의 CAGR로 매년 성장할 것으로 추정됩니다.

백신 유형별로 약독생 백신이 2023년에 가장 높은 시장 점유율을 보였습니다.

전달 방법별로는 2023년에 스프레이가 주요 유형이었습니다.

지역별로는 북미가 2023년 매출을 선도했습니다.

비강 백신 시장-세분화 분석 :

비강 백신 세계 시장은 백신 유형, 전달 방법, 유통 및 지역에 따라 세분화됩니다.

시장은 백신 유형에 따라 5가지로 분류됩니다 : 약독 생 백신, 불활성화 백신, 서브 유닛 백신, 재조합 백신, 접합 백신. 약독 생 백신은 강력한 면역 반응을 자극하는 바이러스의 약독화 백신입니다. 장기간의 면역 지속성을 기대할 수 있기 때문에 큰 성장이 예상됩니다. 그러나 표적 면역 반응을 일으키는 특정 항원을 포함하도록 고안된 재조합 백신도 안전성 프로파일과 제조의 용이성으로 지지를 받고 있습니다.

시장은 전달 방법에 따라 두 가지 범주로 나뉩니다. 스프레이 및 적하. 점비 백신 시장에서는 스프레이가 지배적인 전달 방법이 될 것으로 예상됩니다. 스프레이는 특히 소아 및 주사 바늘을 싫어하는 환자에게 투여하기가 더 쉽고 최적의 면역 반응을 얻기 위해 비강 내에서 더 넓게 백신을 퍼뜨릴 수 있습니다.

비강 백신 시장-지리적 통찰

북미는 확립된 연구 인프라, 백신 개발을 위한 정부 자금, 신기술의 높은 채택률로 현재 큰 점유율을 차지하고 있습니다. 그러나 아시아 태평양이 가장 빠른 성장을 이룰 것으로 예상됩니다. 이 배경에는 호흡기 질환에 걸리기 쉬운 인구 증가와 가처분 소득 증가, 소아 예방접종 프로그램을 추진하는 정부의 대처 등이 있습니다. 유럽은 견고한 규제 프레임 워크와 첨단 백신 연구에 중점을두고 안정적인 시장을 형성하고 있습니다. 남미와 중동 및 아프리카의 신흥 시장은 공중 보건 인프라 개선과 예방 접종의 효과에 대한 의식이 높아짐에 중점을두고 있기 때문에 유망한 가능성을 가지고 있습니다. 각 지역의 규제 요건에 대응하고, 가격면에서 우려에 대처하고, 현지의 요구에 맞추어 전달 시스템을 조정할 수 있는 제조업체는 이 확대하는 시장에 참가하는데 유리한 입장에 있다고 생각됩니다.

비강 백신 시장-경쟁 구도 :

AstraZeneca와 Sanofi Pasteur와 같은 제약 선두는 백신 개발 경험과 세계 유통망에 의해 강한 존재감을 보여주고 있습니다. 그러나 중소형 생명 공학 기업은 혁신적인 전달 시스템과 특정 호흡기 질환을 목표로 한 틈새 백신으로 크게 발전하고 있습니다. 게다가, 학술기관과 연구센터는 새로운 비강 백신 플랫폼 개발에 중요한 역할을 합니다. 이러한 기업들 간의 전략적 제휴는 점차 보편화되고 있으며, 전문 지식을 모아 연구개발을 가속화하고 있습니다. 또한 백신 포트폴리오 확대와 유망한 신기술 진출을 목표로 하는 기존 기업의 합병·인수도 잠재적인 요인이 되고 있습니다. 이러한 경쟁 구도에서 성장하는 비강 백신 시장에서 발판을 구축하려면 혁신, 전략적 파트너십 및 미충족 의료 요구에 대한 노력에 주력해야 합니다.

목차

제1장 비강 백신 시장 개요

  • 조사 범위
  • 시장 추정 연도

제2장 주요 요약

  • 시장 분석
  • 경쟁 인사이트

제3장 비강 백신의 주요 시장 동향

  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
  • 시장의 미래 동향

제4장 비강 백신 산업 조사

  • PEST 분석
  • Porter's Five Forces 분석
  • 성장 전망 맵핑
  • 규제 프레임워크 분석

제5장 비강 백신 시장 : COVID-19의 영향 분석

  • COVID-19 이전의 영향 분석
  • COVID-19 이후의 영향 분석

제6장 비강 백신 시장 상황

  • 비강 백신 시장 점유율 분석(2023년)
  • 주요 제조업체별 분석 데이터
    • 기존 기업 분석
    • 신흥기업 분석

제7장 비강 백신 시장-백신 유형별

  • 개요
    • 백신 유형별 부문 점유율 분석
    • 생약독화 백신
    • 불활화 백신
    • 서브 유닛
    • 재조합
    • 결합 백신

제8장 비강 백신 시장-전달 방법별

  • 개요
    • 전달 방법별 부문 점유율 분석
    • 스프레이식
    • 적하식

제9장 비강 백신 시장-유통별

  • 개요
    • 유통별 부문 점유율 분석
    • 공공
    • 프라이빗

제10장 비강 백신 시장-지역별

  • 소개
  • 북미
    • 개요
    • 북미의 주요 제조업체
    • 미국
    • 캐나다
  • 유럽
    • 개요
    • 유럽의 주요 제조업체
    • 독일
    • 이탈리아
    • 영국
    • 프랑스
    • 러시아
    • 네덜란드
    • 스웨덴
    • 폴란드
    • 기타
  • 아시아 태평양
    • 개요
    • 아시아 태평양의 주요 제조업체
    • 인도
    • 중국
    • 일본
    • 한국
    • 호주
    • 태국
    • 인도네시아
    • 필리핀
    • 기타
  • 남미
    • 개요
    • 남미의 주요 제조업체
    • 브라질
    • 멕시코
    • 아르헨티나
    • 콜롬비아
    • 기타
  • 중동 및 아프리카
    • 개요
    • 중동 및 아프리카의 주요 제조업체
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 이스라엘
    • 터키
    • 알제리
    • 이집트
    • 기타

제11장 주요 벤더 분석-비강 백신 산업

  • 경쟁 대시보드
  • 기업 프로파일
    • Altimmune Inc.
    • AstraZeneca PLC
    • Bharat Biotech International Limited
    • BioDiem, Inc.
    • CanSino Biopharmaceuticals Inc.
    • GlaxoSmithKline plc
    • Iovance Biotherapeutics, Inc.
    • Meda Pharma GmbH
    • MeDiVac, Inc.
    • Pfizer Inc.
    • Sanofi SA
    • Seqirus Holdings Pty Ltd
    • Serum Institute of India Pvt. Ltd.
    • TransBio Inc.
    • Vaxlive Inc.
    • 기타

제12장 애널리스트의 전방위 전망

LYJ

REPORT HIGHLIGHT

Nasal Vaccines Market size was valued at USD 418.9 million in 2023, expanding at a CAGR of 8.56% from 2024 to 2032.

Nasal vaccines, delivered as a spray or mist through the nose, offer a needle-free and potentially more efficient way to trigger immune responses. The growing preference for needle-free vaccinations, particularly among children and needle-phobic individuals. Additionally, nasal vaccines' ability to induce mucosal immunity, potentially providing better protection against respiratory illnesses, fuels market growth. However, challenges like ensuring the stability of the vaccine and navigating stringent regulatory pathways may act as restraints. Exciting opportunities lie in advancements in delivery systems for improved efficacy and the development of vaccines for various respiratory diseases, including COVID-19.

Nasal Vaccines Market- Market Dynamics

Rising prevalence of respiratory infections propelling the market growth

The increasing prevalence of respiratory infections is fueling the growth of the nasal vaccine market, as this technology offers a needle-free alternative to immunization. According to the World Health Organization, respiratory infections account for a significant portion of global mortality, with influenza alone causing an estimated 290,000 to 650,000 deaths annually. This burden, coupled with a growing preference for needle-free vaccinations, is driving the nasal vaccine market. For instance, a recent study published in a reputable medical journal demonstrated that a nasal vaccine for RSV (respiratory syncytial virus) proved effective in protecting infants, highlighting the potential of this. As the fight against respiratory illnesses continues, nasal vaccines are poised to play a more prominent role.

Nasal Vaccines Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.56% over the forecast period (2024-2032)

Based on Vaccine Type segmentation, Live attenuated vaccines were predicted to show maximum market share in the year 2023

Based on Delivery Method segmentation, Spray was the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

Nasal Vaccines Market- Segmentation Analysis:

The Global Nasal Vaccines Market is segmented based on Vaccine Type, Delivery Method, Distribution, and Region.

The market is divided into five categories based on Vaccine Type: Live attenuated vaccines, Inactivated vaccines, Subunit, Recombinant, and Conjugate Vaccines. Live attenuated vaccines, weakened versions of the virus that stimulate a strong immune response, are expected to see significant growth due to their potential for long-lasting immunity. However, recombinant vaccines, engineered to contain specific antigens that trigger a targeted immune response, are also gaining traction due to their safety profile and ease of production.

The market is divided into two categories based on the Delivery Method: Spray and Drop. Spray is anticipated to be the dominant delivery method in the nasal vaccine market. Sprays offer greater ease of administration, particularly for children and those with needle aversion, and ensure a wider distribution of the vaccine within the nasal cavity for optimal immune response.

Nasal Vaccines Market- Geographical Insights

North America currently holds a significant share due to established research infrastructure, government funding for vaccine development, and a high adoption rate of new technologies. However, the Asia Pacific region is expected to witness the fastest growth. This is driven by factors like a large and growing population susceptible to respiratory illnesses, rising disposable income, and government initiatives promoting childhood immunization programs. Europe presents a steady market with a focus on robust regulatory frameworks and advanced vaccine research. Emerging markets in Latin America and the Middle East & Africa offer promising potential due to a growing focus on improving public health infrastructure and increasing awareness of vaccination benefits. Manufacturers who can navigate regional regulatory requirements, address affordability concerns, and tailor their delivery systems to suit local needs will be well-positioned to tap into this expanding market.

Nasal Vaccines Market- Competitive Landscape:

Pharmaceutical giants like AstraZeneca and Sanofi Pasteur hold a strong presence due to their experience in vaccine development and global distribution networks. However, smaller biotechnology companies are making significant strides with innovative delivery systems and niche vaccines targeting specific respiratory illnesses. Additionally, academic institutions and research centers play a crucial role in developing novel nasal vaccine platforms. Strategic collaborations between these entities are becoming increasingly common, leveraging combined expertise to accelerate research and development. Mergers and acquisitions are also a potential factor, with established players seeking to expand their vaccine portfolios or gain access to promising new technologies. This competitive landscape necessitates a focus on innovation, strategic partnerships, and a commitment to addressing unmet medical needs to gain a foothold in the growing nasal vaccine market.

Recent Developments:

In January 2023, Bharat Biotech International Limited (BBIL) and Biotechnology Industry Research Assistance (BIRAC) developed iNNCOVACC, the world's first intranasal COVID-19 vaccine to receive approval for the primary 2-dose schedule and as a heterologous booster dose.

In October 2023, Mylab and Serum Institute of India launched Nasovac S4, India's first needle-free nasal influenza vaccine. The vaccine contains four influenza virus strains and is available through healthcare providers and clinics across India, aligning with WHO recommendations

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NASAL VACCINES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Altimmune Inc.

AstraZeneca PLC

Bharat Biotech International Limited

BioDiem, Inc.

CanSino Biopharmaceuticals Inc.

GlaxoSmithKline plc

Iovance Biotherapeutics, Inc.

Meda Pharma GmbH

MeDiVac, Inc.

Pfizer Inc.

Sanofi S.A.

Seqirus Holdings Pty Ltd

Serum Institute of India Pvt. Ltd.

TransBio Inc.

Vaxlive Inc.

Others

GLOBAL NASAL VACCINES MARKET, BY VACCINE TYPE- MARKET ANALYSIS, 2019 - 2032

  • Live attenuated vaccines
  • Inactivated vaccines
  • Subunit
  • Recombinant
  • Conjugate Vaccines

GLOBAL NASAL VACCINES MARKET, BY DELIVERY METHOD- MARKET ANALYSIS, 2019 - 2032

  • Spray
  • Drop

GLOBAL NASAL VACCINES MARKET, BY DISTRIBUTION- MARKET ANALYSIS, 2019 - 2032

  • Public
  • Private

GLOBAL NASAL VACCINES MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Nasal Vaccines Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Nasal Vaccines Market Snippet by Vaccine Type
    • 2.1.2. Nasal Vaccines Market Snippet by Delivery Method
    • 2.1.3. Nasal Vaccines Market Snippet by Distribution
    • 2.1.4. Nasal Vaccines Market Snippet by Country
    • 2.1.5. Nasal Vaccines Market Snippet by Region
  • 2.2. Competitive Insights

3. Nasal Vaccines Key Market Trends

  • 3.1. Nasal Vaccines Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Nasal Vaccines Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Nasal Vaccines Market Opportunities
  • 3.4. Nasal Vaccines Market Future Trends

4. Nasal Vaccines Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Nasal Vaccines Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Nasal Vaccines Market Landscape

  • 6.1. Nasal Vaccines Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Nasal Vaccines Market - By Vaccine Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Vaccine Type, 2023 & 2032 (%)
    • 7.1.2. Live attenuated vaccines
    • 7.1.3. Inactivated vaccines
    • 7.1.4. Subunit
    • 7.1.5. Recombinant
    • 7.1.6. Conjugate Vaccines

8. Nasal Vaccines Market - By Delivery Method

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Delivery Method, 2023 & 2032 (%)
    • 8.1.2. Spray
    • 8.1.3. Drop

9. Nasal Vaccines Market - By Distribution

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution, 2023 & 2032 (%)
    • 9.1.2. Public
    • 9.1.3. Private

10. Nasal Vaccines Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Nasal Vaccines Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Delivery Method, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Delivery Method, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Delivery Method, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Nasal Vaccines Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Delivery Method, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Delivery Method, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Delivery Method, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Delivery Method, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Delivery Method, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Delivery Method, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Delivery Method, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Delivery Method, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Delivery Method, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Delivery Method, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Nasal Vaccines Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Delivery Method, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Delivery Method, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Delivery Method, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Delivery Method, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Delivery Method, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Delivery Method, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Delivery Method, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Delivery Method, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Delivery Method, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Delivery Method, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Nasal Vaccines Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Delivery Method, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Delivery Method, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Delivery Method, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Delivery Method, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Delivery Method, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Delivery Method, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Nasal Vaccines Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Delivery Method, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Delivery Method, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Delivery Method, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Delivery Method, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Delivery Method, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Delivery Method, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Delivery Method, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Vaccine Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Delivery Method, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Nasal Vaccines Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Altimmune Inc.
    • 11.2.2. AstraZeneca PLC
    • 11.2.3. Bharat Biotech International Limited
    • 11.2.4. BioDiem, Inc.
    • 11.2.5. CanSino Biopharmaceuticals Inc.
    • 11.2.6. GlaxoSmithKline plc
    • 11.2.7. Iovance Biotherapeutics, Inc.
    • 11.2.8. Meda Pharma GmbH
    • 11.2.9. MeDiVac, Inc.
    • 11.2.10. Pfizer Inc.
    • 11.2.11. Sanofi S.A.
    • 11.2.12. Seqirus Holdings Pty Ltd
    • 11.2.13. Serum Institute of India Pvt. Ltd.
    • 11.2.14. TransBio Inc.
    • 11.2.15. Vaxlive Inc.
    • 11.2.16. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제